{"gene":"MYLK3","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2012,"finding":"Cardiac myosin light chain kinase (cMLCK/MYLK3) is the primary kinase that phosphorylates ventricular myosin regulatory light chain 2 (MLC2v) in cardiomyocytes. Loss of cMLCK (Mylk3 knockout mice) reduced MLC2v phosphorylation and led to cardiac failure under pressure overload, while cMLCK overexpression preserved phosphorylation and prevented decompensation. Under pressure overload, cMLCK protein is degraded by the ubiquitin-proteasome system, reducing MLC2v phosphorylation and causing the transition from compensated hypertrophy to decompensated heart failure.","method":"Mylk3 gene-targeted knockout and cardiomyocyte-specific transgenic overexpression in mice; pressure overload (transaortic constriction); ubiquitin-proteasome inhibition","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic models (KO + OE), defined cellular phenotype, mechanistic pathway placement, replicated in subsequent studies","pmids":["23095280"],"is_preprint":false},{"year":2016,"finding":"Acute inducible ablation of cMLCK (MYLK3) in adult cardiomyocytes via tamoxifen-driven Cre recombination caused rapid heart failure within 7 days, with sarcomeric disorganization, wavy fibres, cardiomyocyte atrophy, and reduced fractional shortening. This established that cMLCK is acutely required for maintaining sarcomere integrity and contractility in adult hearts, and that its reduction underlies the transition from compensated to decompensated hypertrophy.","method":"Inducible cardiomyocyte-specific Mylk3 knockout (floxed-Mylk3/merCremer mice); echocardiography; histology; electron microscopy","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean inducible KO with defined cellular and functional phenotypes, multiple orthogonal readouts in a single rigorous study","pmids":["27025239"],"is_preprint":false},{"year":2017,"finding":"Loss-of-function mutations in MYLK3 (a read-through mutation c.2459A>C and a frameshift c.1879_1885del) identified in familial dilated cardiomyopathy patients result in markedly reduced cMLCK protein expression and decreased myosin light chain 2 phosphorylation, establishing MYLK3 mutations as a cause of human DCM.","method":"Whole exome sequencing; segregation analysis; in vitro kinase/phosphorylation assays; immunohistochemistry","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase activity assays combined with protein expression and human genetic segregation analysis","pmids":["29235529"],"is_preprint":false},{"year":2019,"finding":"A truncation mutation in cMLCK (p.Pro639Valfs*15) results in complete loss of kinase activity, as determined by Phos-tag SDS-PAGE (showing absent MLC2v phosphorylation) and ADP-Glo kinase assays (Km = 5.93 ± 1.47 μM and Vmax = 1.28 ± 0.03 mol/min/mol for wild-type; zero activity for mutant). This mutation is associated with familial dilated cardiomyopathy.","method":"Phos-tag SDS-PAGE phosphorylation assays; ADP-Glo kinase activity assays; mutation screening; exome sequencing","journal":"ESC heart failure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay with mutagenesis, two orthogonal methods (Phos-tag + ADP-Glo), single lab","pmids":["30690923"],"is_preprint":false},{"year":2019,"finding":"Heterozygous Mylk3 knockout mice show ~75% reduction in cMLCK protein (despite only ~50% reduction in mRNA), indicating post-transcriptional regulation of cMLCK protein stability, and exhibit mild reduction in cardiac contractility (fractional shortening ~23% vs ~30% in wild-type), partially recapitulating human DCM with heterozygous MYLK3 mutations.","method":"Heterozygous Mylk3 knockout mice; echocardiography; qPCR; Western blot; cardiomyocyte morphometry","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic model with multiple orthogonal methods, single lab","pmids":["31244672"],"is_preprint":false},{"year":2020,"finding":"A null mutation in Mylk3 in C57BL/6N mice abolishes MYLK3 protein expression and causes dilated cardiomyopathy with eccentric hypertrophy, sarcomere disorganization, and differential expression of cardiac remodeling genes, establishing Mylk3 loss as the cause of the C57BL/6N cardiomyopathy phenotype.","method":"RNAseq; variant calling; immunofluorescence of cardiomyocytes; echocardiography; comparison of C57BL/6J and C57BL/6N substrains with BAC transgenic rescue","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including genetic rescue, multiple time points, two substrain comparisons","pmids":["32213617"],"is_preprint":false},{"year":2023,"finding":"cMLCK (MYLK3) regulates cardiac contractility by phosphorylating ventricular myosin regulatory light chain (MLC2v), and reduced cMLCK shifts myosin toward the superrelaxed (SRX) state, impairing contractility. Restoration of cMLCK via AAV9_MYLK3 vector rescued MLC2v phosphorylation, normalized the SRX/DRX ratio, and improved contractile dysfunction in knock-in mice and human iPSC-derived cardiomyocytes carrying a familial DCM MYLK3 frameshift mutation. A small-molecule cMLCK activator (LEUO-1154) increased human cMLCK Vmax ~2-fold without affecting Km.","method":"Knock-in mice (Mylk3+/fs, Mylk3fs/fs); human iPSC-derived cardiomyocytes; AAV9-mediated gene delivery; CRISPR gene correction; in vitro kinase assays; myosin SRX/DRX state measurements; echocardiography","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (gene correction, AAV rescue, small molecule, in vitro kinase assay), human iPSC-CM validation, consistent with prior studies","pmids":["37128901"],"is_preprint":false},{"year":2016,"finding":"Perinatal ablation of cMLCK (MYLK3) causes heart failure with cardiomyocyte elongation (without compensatory thickening), increased heart weight/body weight ratio, reduced fractional shortening, and elevated fetal gene expression. The severity is intermediate between germline knockout (mild dysfunction with hypertrophy) and adult-onset knockout (acute failure with atrophy), establishing that cMLCK's role in cardiomyocyte morphology and function is developmentally regulated.","method":"Perinatal inducible Mylk3 knockout (tamoxifen injection at gestational day 19); echocardiography; cardiomyocyte morphometry; gene expression analysis","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic model with functional and morphological readouts, single lab, comparison across developmental stages","pmids":["27833563"],"is_preprint":false},{"year":2012,"finding":"miR-1 post-transcriptionally downregulates cMLCK (MYLK3) by targeting the 3'UTR of MYLK3, leading to decreased MLC2v phosphorylation, sarcomere assembly defects, and impaired cardiac contractile function. This identifies miR-1 as a negative regulator of cMLCK.","method":"Cardiac-specific miR-1 transgenic mice; 3'UTR reporter assays; protein expression analysis; phosphorylation assays; electron microscopy; locked nucleic acid anti-miR rescue","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'UTR targeting confirmed, rescue experiment with anti-miR, multiple readouts, single lab","pmids":["22719074"],"is_preprint":false},{"year":2025,"finding":"SQSTM1/p62 (sequestosome 1) physically interacts with MYLK3 and drives its excessive autophagic degradation in sunitinib-treated iPSC-derived cardiomyocytes. Downregulation of MYLK3 suppresses CAMK2 phosphorylation, which reduces phosphorylation of phospholamban (PLN), thereby impairing ATP2A2a/SERCA2a activity, causing Ca2+ dyshomeostasis and arrhythmia. Overexpression of MYLK3 or treatment with omecamtiv mecarbil reversed these pathological phenotypes.","method":"Human iPSC-derived cardiomyocytes; co-immunoprecipitation (SQSTM1-MYLK3 interaction); autophagy flux assays; CAMK2/PLN/SERCA2a phosphorylation assays; MYLK3 overexpression; omecamtiv mecarbil treatment; mouse in vivo nanoparticle delivery","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, multiple downstream pathway readouts, rescue experiments; single lab","pmids":["40568844"],"is_preprint":false},{"year":2026,"finding":"Osimertinib causes cardiac dysfunction by dephosphorylating GATA4, which represses MYLK3 transcription, leading to reduced MYLK3 expression, decreased MYL2 (MLC2v) phosphorylation, and sarcomere disarray. This identifies the GATA4–MYLK3–MYL2 axis as the mechanism of osimertinib-induced cardiotoxicity, which is reversible upon drug discontinuation and preventable with the myosin activator omecamtiv.","method":"Human iPSC-derived cardiomyocytes; mouse transverse aortic constriction model; single-nucleus RNA sequencing; in vitro phosphorylation assays; omecamtiv mecarbil intervention","journal":"European heart journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — snRNAseq plus in vitro assays plus rescue pharmacology; GATA4-MYLK3 transcriptional link not fully validated by direct promoter assay in abstract","pmids":["41330421"],"is_preprint":false},{"year":2023,"finding":"GPR65 overexpression in trophoblast cells under acidic conditions activates cAMP-ERK signaling, upregulates MYLK3 expression, and subsequently downregulates fibronectin, thereby inhibiting cell adhesion, migration, and invasion.","method":"HTR-8/SVneo cell overexpression and siRNA knockdown; JAR spheroid and mouse blastocyst adhesion assays; Western blot; pathway inhibitor experiments","journal":"Cell communication and signaling : CCS","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, gene expression changes with functional readout but indirect pathway placement for MYLK3 specifically; MYLK3 not directly manipulated","pmids":["37723567"],"is_preprint":false}],"current_model":"MYLK3 (cMLCK) is a cardiac-specific serine/threonine kinase that phosphorylates ventricular myosin regulatory light chain 2 (MLC2v) at the head-rod junction of cardiac myosin, promoting actin-myosin interactions and enhancing sarcomere organization and cardiac contractility; loss of cMLCK shifts myosin toward the superrelaxed (SRX) state, causes sarcomeric disorganization and heart failure, and is degraded by the ubiquitin-proteasome system under pressure overload (a process involving SQSTM1/p62-mediated autophagy in drug toxicity contexts) and transcriptionally repressed via GATA4 dephosphorylation; downstream, MYLK3 also regulates CAMK2-PLN-SERCA2a Ca²⁺ handling, and loss-of-function mutations in MYLK3 cause familial dilated cardiomyopathy in humans."},"narrative":{"mechanistic_narrative":"MYLK3 (cMLCK) is a cardiac serine/threonine kinase that maintains sarcomere integrity and contractility by phosphorylating ventricular myosin regulatory light chain 2 (MLC2v/MYL2) in cardiomyocytes [PMID:23095280]. This phosphorylation keeps myosin biased away from the energy-sparing superrelaxed (SRX) state; loss of cMLCK shifts myosin toward SRX, disorganizes the sarcomere, and impairs contraction, while restoring cMLCK by AAV9_MYLK3 delivery normalizes the SRX/DRX ratio and rescues contractile function in mouse and human iPSC-derived cardiomyocyte models [PMID:37128901]. cMLCK is acutely and continuously required: inducible ablation in adult hearts produces rapid heart failure with sarcomeric disorganization and cardiomyocyte atrophy within days [PMID:27025239], and its phenotypic role is developmentally regulated across germline, perinatal, and adult onset [PMID:27833563]. Loss-of-function and truncating MYLK3 mutations that abolish kinase activity and reduce cMLCK protein cause familial dilated cardiomyopathy in humans [PMID:29235529, PMID:30690923], a link reinforced by a null Mylk3 allele driving the C57BL/6N substrain cardiomyopathy with BAC transgenic rescue [PMID:32213617]. cMLCK abundance is tightly controlled post-transcriptionally and is destabilized by the ubiquitin-proteasome system under pressure overload [PMID:23095280], repressed by miR-1 targeting the MYLK3 3'UTR [PMID:22719074], and degraded via SQSTM1/p62-driven autophagy in drug-toxicity contexts, where reduced MYLK3 suppresses CAMK2-PLN-SERCA2a Ca2+ handling and provokes arrhythmia [PMID:40568844]. Transcriptionally, GATA4 dephosphorylation represses MYLK3 in osimertinib cardiotoxicity, defining a GATA4-MYLK3-MYL2 axis [PMID:41330421].","teleology":[{"year":2012,"claim":"Established that cMLCK is the principal kinase phosphorylating MLC2v in vivo and that its proteasomal loss precipitates decompensated heart failure, defining the core kinase-substrate axis and a disease-relevant degradation mechanism.","evidence":"Reciprocal Mylk3 knockout and cardiomyocyte-specific overexpression in mice with pressure overload and proteasome inhibition","pmids":["23095280"],"confidence":"High","gaps":["Did not resolve which E3 ligase targets cMLCK","Mechanism coupling MLC2v phosphorylation to contractile output not yet defined at the myosin level"]},{"year":2012,"claim":"Identified miR-1 as a negative post-transcriptional regulator of cMLCK, explaining how MYLK3 abundance and downstream MLC2v phosphorylation can be tuned independent of gene dosage.","evidence":"Cardiac-specific miR-1 transgenic mice, MYLK3 3'UTR reporter assays, and anti-miR rescue","pmids":["22719074"],"confidence":"Medium","gaps":["Did not establish physiological contexts where endogenous miR-1 controls cMLCK","Other regulatory miRNAs not surveyed"]},{"year":2016,"claim":"Demonstrated that cMLCK is acutely required in mature cardiomyocytes for sarcomere integrity, distinguishing maintenance roles from developmental ones.","evidence":"Tamoxifen-inducible cardiomyocyte-specific Mylk3 knockout with echocardiography, histology, and electron microscopy","pmids":["27025239"],"confidence":"High","gaps":["Did not define the molecular basis of cardiomyocyte atrophy versus hypertrophy","Reversibility of acute ablation not tested"]},{"year":2016,"claim":"Showed that cMLCK's effect on cardiomyocyte morphology is developmentally staged, with perinatal loss yielding an intermediate phenotype between germline and adult ablation.","evidence":"Perinatal inducible Mylk3 knockout with morphometry and fetal gene expression analysis","pmids":["27833563"],"confidence":"Medium","gaps":["Mechanism underlying stage-dependent morphological responses unresolved","Single-lab observation"]},{"year":2017,"claim":"Connected human MYLK3 loss-of-function mutations to familial dilated cardiomyopathy via reduced protein and reduced MLC2v phosphorylation.","evidence":"Whole exome sequencing, segregation analysis, and in vitro phosphorylation assays in DCM families","pmids":["29235529"],"confidence":"High","gaps":["Did not establish per-mutation effects on enzyme kinetics","Genotype-phenotype variability across carriers not detailed"]},{"year":2019,"claim":"Quantified that a truncating cMLCK mutation produces complete loss of kinase activity, providing direct enzymatic confirmation of pathogenicity.","evidence":"Phos-tag SDS-PAGE and ADP-Glo kinase assays with kinetic parameters for wild-type versus mutant","pmids":["30690923"],"confidence":"High","gaps":["Did not assess in vivo consequences of this specific allele","Effect on protein stability versus catalysis not dissected"]},{"year":2019,"claim":"Revealed post-transcriptional control of cMLCK protein stability, since heterozygous loss reduced protein ~75% despite only ~50% mRNA reduction, linking dosage to mild contractile deficit.","evidence":"Heterozygous Mylk3 knockout mice with echocardiography, qPCR, and Western blot","pmids":["31244672"],"confidence":"Medium","gaps":["Did not identify the stability-controlling factors","Single-lab model"]},{"year":2020,"claim":"Confirmed Mylk3 loss as causal for cardiomyopathy by attributing the C57BL/6N substrain phenotype to a null allele rescued by BAC transgenesis.","evidence":"Substrain comparison, RNAseq, variant calling, and BAC transgenic rescue with echocardiography","pmids":["32213617"],"confidence":"High","gaps":["Did not map downstream remodeling effectors","Strain-specific modifiers not excluded"]},{"year":2023,"claim":"Mechanistically tied cMLCK to the myosin superrelaxed state and demonstrated therapeutic rescue, establishing both the biophysical readout and translational strategies.","evidence":"Knock-in mice, human iPSC-CMs, AAV9-MYLK3 delivery, CRISPR correction, SRX/DRX measurement, and a small-molecule cMLCK activator","pmids":["37128901"],"confidence":"High","gaps":["Durability and safety of AAV9 and activator approaches not established","Structural basis of activator action on Vmax not resolved"]},{"year":2025,"claim":"Linked SQSTM1/p62-mediated autophagic degradation of MYLK3 to CAMK2-PLN-SERCA2a Ca2+ dyshomeostasis, extending cMLCK biology to drug-induced arrhythmia.","evidence":"iPSC-CMs with SQSTM1-MYLK3 co-immunoprecipitation, autophagy flux and phosphorylation assays, and rescue by MYLK3 overexpression or omecamtiv mecarbil","pmids":["40568844"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal validation of the SQSTM1-MYLK3 interaction","Direct mechanism coupling cMLCK to CAMK2 phosphorylation not defined"]},{"year":2026,"claim":"Defined a GATA4-MYLK3-MYL2 transcriptional axis underlying osimertinib cardiotoxicity, broadening regulation of cMLCK to transcriptional repression.","evidence":"iPSC-CMs, TAC mouse model, single-nucleus RNA sequencing, and omecamtiv rescue","pmids":["41330421"],"confidence":"Medium","gaps":["GATA4-MYLK3 link not confirmed by direct promoter binding assay","Generalizability beyond osimertinib not established"]},{"year":null,"claim":"How cMLCK abundance is integrated across competing proteasomal, autophagic, microRNA, and transcriptional inputs to set MLC2v phosphorylation in different physiological and stress contexts remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of cMLCK turnover control","E3 ligase mediating proteasomal degradation unidentified","Direct kinase-level link between cMLCK and CAMK2 signaling unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,3,6]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[1,5]}],"pathway":[{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,5]}],"complexes":[],"partners":["MYL2","SQSTM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q32MK0","full_name":"Myosin light chain kinase 3","aliases":["Cardiac-MyBP-C-associated Ca/CaM kinase","Cardiac-MLCK"],"length_aa":819,"mass_kda":88.4,"function":"Kinase that phosphorylates MYL2 in vitro. Promotes sarcomere formation in cardiomyocytes and increases cardiomyocyte contractility (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q32MK0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MYLK3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MYLK3","total_profiled":1310},"omim":[{"mim_id":"612147","title":"MYOSIN LIGHT CHAIN KINASE 3; MYLK3","url":"https://www.omim.org/entry/612147"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"heart muscle","ntpm":96.8},{"tissue":"skeletal muscle","ntpm":43.4},{"tissue":"tongue","ntpm":67.7}],"url":"https://www.proteinatlas.org/search/MYLK3"},"hgnc":{"alias_symbol":["caMLCK","MLCK"],"prev_symbol":[]},"alphafold":{"accession":"Q32MK0","domains":[{"cath_id":"3.30.200.20","chopping":"508-592","consensus_level":"medium","plddt":93.188,"start":508,"end":592},{"cath_id":"1.10.510.10","chopping":"593-793","consensus_level":"medium","plddt":91.976,"start":593,"end":793}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q32MK0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q32MK0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q32MK0-F1-predicted_aligned_error_v6.png","plddt_mean":61.72},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MYLK3","jax_strain_url":"https://www.jax.org/strain/search?query=MYLK3"},"sequence":{"accession":"Q32MK0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q32MK0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q32MK0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q32MK0"}},"corpus_meta":[{"pmid":"19027740","id":"PMC_19027740","title":"Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis.","date":"2008","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19027740","citation_count":348,"is_preprint":false},{"pmid":"26948423","id":"PMC_26948423","title":"TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26948423","citation_count":170,"is_preprint":false},{"pmid":"23095280","id":"PMC_23095280","title":"Myosin light chain phosphorylation is critical for adaptation to cardiac stress.","date":"2012","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/23095280","citation_count":91,"is_preprint":false},{"pmid":"22719074","id":"PMC_22719074","title":"Overexpression of microRNA-1 impairs cardiac contractile function by damaging sarcomere assembly.","date":"2012","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/22719074","citation_count":56,"is_preprint":false},{"pmid":"28795125","id":"PMC_28795125","title":"The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability.","date":"2017","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28795125","citation_count":50,"is_preprint":false},{"pmid":"32213617","id":"PMC_32213617","title":"Mylk3 null C57BL/6N mice develop cardiomyopathy, whereas Nnt null C57BL/6J mice do not.","date":"2020","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/32213617","citation_count":35,"is_preprint":false},{"pmid":"27025239","id":"PMC_27025239","title":"Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/27025239","citation_count":32,"is_preprint":false},{"pmid":"29235529","id":"PMC_29235529","title":"Identification of MYLK3 mutations in familial dilated cardiomyopathy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29235529","citation_count":31,"is_preprint":false},{"pmid":"36314488","id":"PMC_36314488","title":"Circulating Soluble CD163, Associations With Cardiovascular Outcomes and Mortality, and Identification of Genetic Variants in Older Individuals: The Cardiovascular Health Study.","date":"2022","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/36314488","citation_count":25,"is_preprint":false},{"pmid":"37128901","id":"PMC_37128901","title":"Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37128901","citation_count":22,"is_preprint":false},{"pmid":"30690923","id":"PMC_30690923","title":"Impact of cardiac myosin light chain kinase gene mutation on development of dilated cardiomyopathy.","date":"2019","source":"ESC heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/30690923","citation_count":19,"is_preprint":false},{"pmid":"35651943","id":"PMC_35651943","title":"Genome-Wide Identification and Characterization of Long Non-Coding RNAs in Longissimus dorsi Skeletal Muscle of Shandong Black Cattle and Luxi Cattle.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35651943","citation_count":19,"is_preprint":false},{"pmid":"31566189","id":"PMC_31566189","title":"Inhibitory effect of octyl-phenol and bisphenol A on calcium signaling in cardiomyocyte differentiation of mouse embryonic stem cells.","date":"2019","source":"Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","url":"https://pubmed.ncbi.nlm.nih.gov/31566189","citation_count":18,"is_preprint":false},{"pmid":"28350786","id":"PMC_28350786","title":"Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28350786","citation_count":17,"is_preprint":false},{"pmid":"38092774","id":"PMC_38092774","title":"Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38092774","citation_count":17,"is_preprint":false},{"pmid":"37723567","id":"PMC_37723567","title":"GPR65 inhibits human trophoblast cell adhesion through upregulation of MYLK and downregulation of fibronectin via cAMP-ERK signaling in a low pH environment.","date":"2023","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/37723567","citation_count":10,"is_preprint":false},{"pmid":"27833563","id":"PMC_27833563","title":"Heart Failure Induced by Perinatal Ablation of Cardiac Myosin Light Chain Kinase.","date":"2016","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27833563","citation_count":7,"is_preprint":false},{"pmid":"35509066","id":"PMC_35509066","title":"Four calcium signaling pathway-related genes were upregulated in microcystic adnexal carcinoma: transcriptome analysis and immunohistochemical validation.","date":"2022","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35509066","citation_count":6,"is_preprint":false},{"pmid":"30289599","id":"PMC_30289599","title":"Copy number variants in hypoplastic right heart syndrome.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30289599","citation_count":6,"is_preprint":false},{"pmid":"27264040","id":"PMC_27264040","title":"Inhibitory effect of progesterone during early embryonic development: Suppression of myocardial differentiation and calcium-related transcriptome by progesterone in mESCs: Progesterone disturb cardiac differentiation of mESCs through lower cytosolic Ca(2.).","date":"2016","source":"Reproductive toxicology (Elmsford, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27264040","citation_count":6,"is_preprint":false},{"pmid":"31244672","id":"PMC_31244672","title":"Heterozygous Mylk3 Knockout Mice Partially Recapitulate Human DCM With Heterozygous MYLK3 Mutations.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31244672","citation_count":5,"is_preprint":false},{"pmid":"37390971","id":"PMC_37390971","title":"An erythrocyte-centric view on the MFSD2B sphingosine-1-phosphate transporter.","date":"2023","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37390971","citation_count":5,"is_preprint":false},{"pmid":"36912226","id":"PMC_36912226","title":"Challenges in the diagnosis and treatment of the malignant adnexal neoplasms of the head and neck.","date":"2023","source":"Current opinion in otolaryngology & head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/36912226","citation_count":4,"is_preprint":false},{"pmid":"39007510","id":"PMC_39007510","title":"A matter of food and substrain: obesogenic diets induce differential severity of cardiac remodeling in C57Bl/6J and C57Bl/6N substrains.","date":"2024","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/39007510","citation_count":4,"is_preprint":false},{"pmid":"40568844","id":"PMC_40568844","title":"Excessive autophagic degradation of MYLK3 causes sunitinib-induced cardiotoxicity.","date":"2025","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/40568844","citation_count":3,"is_preprint":false},{"pmid":"41330421","id":"PMC_41330421","title":"Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis.","date":"2026","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/41330421","citation_count":3,"is_preprint":false},{"pmid":"40898233","id":"PMC_40898233","title":"The circRNA-mediated ceRNA molecular regulatory network in fatigue-type type 2 diabete.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40898233","citation_count":3,"is_preprint":false},{"pmid":"35886011","id":"PMC_35886011","title":"Identification of Recurrent Chromosome Breaks Underlying Structural Rearrangements in Mammary Cancer Cell Lines.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35886011","citation_count":3,"is_preprint":false},{"pmid":"39850559","id":"PMC_39850559","title":"Berberrubine protects against cisplatin-induced ototoxicity by promoting folate biosynthesis.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39850559","citation_count":3,"is_preprint":false},{"pmid":"40646471","id":"PMC_40646471","title":"Genome-wide association studies and candidate genes networks affecting reproductive traits using Iranian Holstein sequence data.","date":"2025","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40646471","citation_count":3,"is_preprint":false},{"pmid":"38949516","id":"PMC_38949516","title":"Genome-wide comparative analyses highlight selection signatures underlying saline adaptation in Chilika buffalo.","date":"2024","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38949516","citation_count":2,"is_preprint":false},{"pmid":"37397988","id":"PMC_37397988","title":"Analyzing aberrant DNA methylation in Colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients.","date":"2023","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/37397988","citation_count":1,"is_preprint":false},{"pmid":"41219836","id":"PMC_41219836","title":"Transcriptomic profiling reveals tissue-specific and sex-dimorphic lipid storage in Bufo gargarizans.","date":"2025","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41219836","citation_count":1,"is_preprint":false},{"pmid":"37760246","id":"PMC_37760246","title":"Canine Somatic Mutations from Whole-Exome Sequencing of B-Cell Lymphomas in Six Canine Breeds-A Preliminary Study.","date":"2023","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/37760246","citation_count":0,"is_preprint":false},{"pmid":"39037491","id":"PMC_39037491","title":"DNA Methylation Profiling in Genetically Selected Clarias magur (Hamilton, 1822) Provides Insights into the Epigenetic Regulation of Growth and Development.","date":"2024","source":"Marine biotechnology (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39037491","citation_count":0,"is_preprint":false},{"pmid":"41007288","id":"PMC_41007288","title":"Grazing-Induced Changes in circRNAs, miRNAs and mRNAs Expression in Tibetan Sheep Biceps Femoris.","date":"2025","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41007288","citation_count":0,"is_preprint":false},{"pmid":"41594893","id":"PMC_41594893","title":"Exercise-Induced Meat Quality Improvement Is Associated with an lncRNA-miRNA-mRNA Network in Tibetan Sheep.","date":"2026","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41594893","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23784,"output_tokens":3595,"usd":0.062638,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11196,"output_tokens":3652,"usd":0.07364,"stage2_stop_reason":"end_turn"},"total_usd":0.136278,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"Cardiac myosin light chain kinase (cMLCK/MYLK3) is the primary kinase that phosphorylates ventricular myosin regulatory light chain 2 (MLC2v) in cardiomyocytes. Loss of cMLCK (Mylk3 knockout mice) reduced MLC2v phosphorylation and led to cardiac failure under pressure overload, while cMLCK overexpression preserved phosphorylation and prevented decompensation. Under pressure overload, cMLCK protein is degraded by the ubiquitin-proteasome system, reducing MLC2v phosphorylation and causing the transition from compensated hypertrophy to decompensated heart failure.\",\n      \"method\": \"Mylk3 gene-targeted knockout and cardiomyocyte-specific transgenic overexpression in mice; pressure overload (transaortic constriction); ubiquitin-proteasome inhibition\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic models (KO + OE), defined cellular phenotype, mechanistic pathway placement, replicated in subsequent studies\",\n      \"pmids\": [\"23095280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Acute inducible ablation of cMLCK (MYLK3) in adult cardiomyocytes via tamoxifen-driven Cre recombination caused rapid heart failure within 7 days, with sarcomeric disorganization, wavy fibres, cardiomyocyte atrophy, and reduced fractional shortening. This established that cMLCK is acutely required for maintaining sarcomere integrity and contractility in adult hearts, and that its reduction underlies the transition from compensated to decompensated hypertrophy.\",\n      \"method\": \"Inducible cardiomyocyte-specific Mylk3 knockout (floxed-Mylk3/merCremer mice); echocardiography; histology; electron microscopy\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean inducible KO with defined cellular and functional phenotypes, multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"27025239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss-of-function mutations in MYLK3 (a read-through mutation c.2459A>C and a frameshift c.1879_1885del) identified in familial dilated cardiomyopathy patients result in markedly reduced cMLCK protein expression and decreased myosin light chain 2 phosphorylation, establishing MYLK3 mutations as a cause of human DCM.\",\n      \"method\": \"Whole exome sequencing; segregation analysis; in vitro kinase/phosphorylation assays; immunohistochemistry\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase activity assays combined with protein expression and human genetic segregation analysis\",\n      \"pmids\": [\"29235529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A truncation mutation in cMLCK (p.Pro639Valfs*15) results in complete loss of kinase activity, as determined by Phos-tag SDS-PAGE (showing absent MLC2v phosphorylation) and ADP-Glo kinase assays (Km = 5.93 ± 1.47 μM and Vmax = 1.28 ± 0.03 mol/min/mol for wild-type; zero activity for mutant). This mutation is associated with familial dilated cardiomyopathy.\",\n      \"method\": \"Phos-tag SDS-PAGE phosphorylation assays; ADP-Glo kinase activity assays; mutation screening; exome sequencing\",\n      \"journal\": \"ESC heart failure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay with mutagenesis, two orthogonal methods (Phos-tag + ADP-Glo), single lab\",\n      \"pmids\": [\"30690923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Heterozygous Mylk3 knockout mice show ~75% reduction in cMLCK protein (despite only ~50% reduction in mRNA), indicating post-transcriptional regulation of cMLCK protein stability, and exhibit mild reduction in cardiac contractility (fractional shortening ~23% vs ~30% in wild-type), partially recapitulating human DCM with heterozygous MYLK3 mutations.\",\n      \"method\": \"Heterozygous Mylk3 knockout mice; echocardiography; qPCR; Western blot; cardiomyocyte morphometry\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic model with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"31244672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A null mutation in Mylk3 in C57BL/6N mice abolishes MYLK3 protein expression and causes dilated cardiomyopathy with eccentric hypertrophy, sarcomere disorganization, and differential expression of cardiac remodeling genes, establishing Mylk3 loss as the cause of the C57BL/6N cardiomyopathy phenotype.\",\n      \"method\": \"RNAseq; variant calling; immunofluorescence of cardiomyocytes; echocardiography; comparison of C57BL/6J and C57BL/6N substrains with BAC transgenic rescue\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including genetic rescue, multiple time points, two substrain comparisons\",\n      \"pmids\": [\"32213617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"cMLCK (MYLK3) regulates cardiac contractility by phosphorylating ventricular myosin regulatory light chain (MLC2v), and reduced cMLCK shifts myosin toward the superrelaxed (SRX) state, impairing contractility. Restoration of cMLCK via AAV9_MYLK3 vector rescued MLC2v phosphorylation, normalized the SRX/DRX ratio, and improved contractile dysfunction in knock-in mice and human iPSC-derived cardiomyocytes carrying a familial DCM MYLK3 frameshift mutation. A small-molecule cMLCK activator (LEUO-1154) increased human cMLCK Vmax ~2-fold without affecting Km.\",\n      \"method\": \"Knock-in mice (Mylk3+/fs, Mylk3fs/fs); human iPSC-derived cardiomyocytes; AAV9-mediated gene delivery; CRISPR gene correction; in vitro kinase assays; myosin SRX/DRX state measurements; echocardiography\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (gene correction, AAV rescue, small molecule, in vitro kinase assay), human iPSC-CM validation, consistent with prior studies\",\n      \"pmids\": [\"37128901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Perinatal ablation of cMLCK (MYLK3) causes heart failure with cardiomyocyte elongation (without compensatory thickening), increased heart weight/body weight ratio, reduced fractional shortening, and elevated fetal gene expression. The severity is intermediate between germline knockout (mild dysfunction with hypertrophy) and adult-onset knockout (acute failure with atrophy), establishing that cMLCK's role in cardiomyocyte morphology and function is developmentally regulated.\",\n      \"method\": \"Perinatal inducible Mylk3 knockout (tamoxifen injection at gestational day 19); echocardiography; cardiomyocyte morphometry; gene expression analysis\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic model with functional and morphological readouts, single lab, comparison across developmental stages\",\n      \"pmids\": [\"27833563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-1 post-transcriptionally downregulates cMLCK (MYLK3) by targeting the 3'UTR of MYLK3, leading to decreased MLC2v phosphorylation, sarcomere assembly defects, and impaired cardiac contractile function. This identifies miR-1 as a negative regulator of cMLCK.\",\n      \"method\": \"Cardiac-specific miR-1 transgenic mice; 3'UTR reporter assays; protein expression analysis; phosphorylation assays; electron microscopy; locked nucleic acid anti-miR rescue\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'UTR targeting confirmed, rescue experiment with anti-miR, multiple readouts, single lab\",\n      \"pmids\": [\"22719074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SQSTM1/p62 (sequestosome 1) physically interacts with MYLK3 and drives its excessive autophagic degradation in sunitinib-treated iPSC-derived cardiomyocytes. Downregulation of MYLK3 suppresses CAMK2 phosphorylation, which reduces phosphorylation of phospholamban (PLN), thereby impairing ATP2A2a/SERCA2a activity, causing Ca2+ dyshomeostasis and arrhythmia. Overexpression of MYLK3 or treatment with omecamtiv mecarbil reversed these pathological phenotypes.\",\n      \"method\": \"Human iPSC-derived cardiomyocytes; co-immunoprecipitation (SQSTM1-MYLK3 interaction); autophagy flux assays; CAMK2/PLN/SERCA2a phosphorylation assays; MYLK3 overexpression; omecamtiv mecarbil treatment; mouse in vivo nanoparticle delivery\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, multiple downstream pathway readouts, rescue experiments; single lab\",\n      \"pmids\": [\"40568844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Osimertinib causes cardiac dysfunction by dephosphorylating GATA4, which represses MYLK3 transcription, leading to reduced MYLK3 expression, decreased MYL2 (MLC2v) phosphorylation, and sarcomere disarray. This identifies the GATA4–MYLK3–MYL2 axis as the mechanism of osimertinib-induced cardiotoxicity, which is reversible upon drug discontinuation and preventable with the myosin activator omecamtiv.\",\n      \"method\": \"Human iPSC-derived cardiomyocytes; mouse transverse aortic constriction model; single-nucleus RNA sequencing; in vitro phosphorylation assays; omecamtiv mecarbil intervention\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — snRNAseq plus in vitro assays plus rescue pharmacology; GATA4-MYLK3 transcriptional link not fully validated by direct promoter assay in abstract\",\n      \"pmids\": [\"41330421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPR65 overexpression in trophoblast cells under acidic conditions activates cAMP-ERK signaling, upregulates MYLK3 expression, and subsequently downregulates fibronectin, thereby inhibiting cell adhesion, migration, and invasion.\",\n      \"method\": \"HTR-8/SVneo cell overexpression and siRNA knockdown; JAR spheroid and mouse blastocyst adhesion assays; Western blot; pathway inhibitor experiments\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, gene expression changes with functional readout but indirect pathway placement for MYLK3 specifically; MYLK3 not directly manipulated\",\n      \"pmids\": [\"37723567\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MYLK3 (cMLCK) is a cardiac-specific serine/threonine kinase that phosphorylates ventricular myosin regulatory light chain 2 (MLC2v) at the head-rod junction of cardiac myosin, promoting actin-myosin interactions and enhancing sarcomere organization and cardiac contractility; loss of cMLCK shifts myosin toward the superrelaxed (SRX) state, causes sarcomeric disorganization and heart failure, and is degraded by the ubiquitin-proteasome system under pressure overload (a process involving SQSTM1/p62-mediated autophagy in drug toxicity contexts) and transcriptionally repressed via GATA4 dephosphorylation; downstream, MYLK3 also regulates CAMK2-PLN-SERCA2a Ca²⁺ handling, and loss-of-function mutations in MYLK3 cause familial dilated cardiomyopathy in humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MYLK3 (cMLCK) is a cardiac serine/threonine kinase that maintains sarcomere integrity and contractility by phosphorylating ventricular myosin regulatory light chain 2 (MLC2v/MYL2) in cardiomyocytes [#0]. This phosphorylation keeps myosin biased away from the energy-sparing superrelaxed (SRX) state; loss of cMLCK shifts myosin toward SRX, disorganizes the sarcomere, and impairs contraction, while restoring cMLCK by AAV9_MYLK3 delivery normalizes the SRX/DRX ratio and rescues contractile function in mouse and human iPSC-derived cardiomyocyte models [#6]. cMLCK is acutely and continuously required: inducible ablation in adult hearts produces rapid heart failure with sarcomeric disorganization and cardiomyocyte atrophy within days [#1], and its phenotypic role is developmentally regulated across germline, perinatal, and adult onset [#7]. Loss-of-function and truncating MYLK3 mutations that abolish kinase activity and reduce cMLCK protein cause familial dilated cardiomyopathy in humans [#2, #3], a link reinforced by a null Mylk3 allele driving the C57BL/6N substrain cardiomyopathy with BAC transgenic rescue [#5]. cMLCK abundance is tightly controlled post-transcriptionally and is destabilized by the ubiquitin-proteasome system under pressure overload [#0], repressed by miR-1 targeting the MYLK3 3'UTR [#8], and degraded via SQSTM1/p62-driven autophagy in drug-toxicity contexts, where reduced MYLK3 suppresses CAMK2-PLN-SERCA2a Ca2+ handling and provokes arrhythmia [#9]. Transcriptionally, GATA4 dephosphorylation represses MYLK3 in osimertinib cardiotoxicity, defining a GATA4-MYLK3-MYL2 axis [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that cMLCK is the principal kinase phosphorylating MLC2v in vivo and that its proteasomal loss precipitates decompensated heart failure, defining the core kinase-substrate axis and a disease-relevant degradation mechanism.\",\n      \"evidence\": \"Reciprocal Mylk3 knockout and cardiomyocyte-specific overexpression in mice with pressure overload and proteasome inhibition\",\n      \"pmids\": [\"23095280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which E3 ligase targets cMLCK\", \"Mechanism coupling MLC2v phosphorylation to contractile output not yet defined at the myosin level\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified miR-1 as a negative post-transcriptional regulator of cMLCK, explaining how MYLK3 abundance and downstream MLC2v phosphorylation can be tuned independent of gene dosage.\",\n      \"evidence\": \"Cardiac-specific miR-1 transgenic mice, MYLK3 3'UTR reporter assays, and anti-miR rescue\",\n      \"pmids\": [\"22719074\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish physiological contexts where endogenous miR-1 controls cMLCK\", \"Other regulatory miRNAs not surveyed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that cMLCK is acutely required in mature cardiomyocytes for sarcomere integrity, distinguishing maintenance roles from developmental ones.\",\n      \"evidence\": \"Tamoxifen-inducible cardiomyocyte-specific Mylk3 knockout with echocardiography, histology, and electron microscopy\",\n      \"pmids\": [\"27025239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular basis of cardiomyocyte atrophy versus hypertrophy\", \"Reversibility of acute ablation not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that cMLCK's effect on cardiomyocyte morphology is developmentally staged, with perinatal loss yielding an intermediate phenotype between germline and adult ablation.\",\n      \"evidence\": \"Perinatal inducible Mylk3 knockout with morphometry and fetal gene expression analysis\",\n      \"pmids\": [\"27833563\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism underlying stage-dependent morphological responses unresolved\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected human MYLK3 loss-of-function mutations to familial dilated cardiomyopathy via reduced protein and reduced MLC2v phosphorylation.\",\n      \"evidence\": \"Whole exome sequencing, segregation analysis, and in vitro phosphorylation assays in DCM families\",\n      \"pmids\": [\"29235529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish per-mutation effects on enzyme kinetics\", \"Genotype-phenotype variability across carriers not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Quantified that a truncating cMLCK mutation produces complete loss of kinase activity, providing direct enzymatic confirmation of pathogenicity.\",\n      \"evidence\": \"Phos-tag SDS-PAGE and ADP-Glo kinase assays with kinetic parameters for wild-type versus mutant\",\n      \"pmids\": [\"30690923\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not assess in vivo consequences of this specific allele\", \"Effect on protein stability versus catalysis not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed post-transcriptional control of cMLCK protein stability, since heterozygous loss reduced protein ~75% despite only ~50% mRNA reduction, linking dosage to mild contractile deficit.\",\n      \"evidence\": \"Heterozygous Mylk3 knockout mice with echocardiography, qPCR, and Western blot\",\n      \"pmids\": [\"31244672\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the stability-controlling factors\", \"Single-lab model\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Confirmed Mylk3 loss as causal for cardiomyopathy by attributing the C57BL/6N substrain phenotype to a null allele rescued by BAC transgenesis.\",\n      \"evidence\": \"Substrain comparison, RNAseq, variant calling, and BAC transgenic rescue with echocardiography\",\n      \"pmids\": [\"32213617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map downstream remodeling effectors\", \"Strain-specific modifiers not excluded\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mechanistically tied cMLCK to the myosin superrelaxed state and demonstrated therapeutic rescue, establishing both the biophysical readout and translational strategies.\",\n      \"evidence\": \"Knock-in mice, human iPSC-CMs, AAV9-MYLK3 delivery, CRISPR correction, SRX/DRX measurement, and a small-molecule cMLCK activator\",\n      \"pmids\": [\"37128901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability and safety of AAV9 and activator approaches not established\", \"Structural basis of activator action on Vmax not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked SQSTM1/p62-mediated autophagic degradation of MYLK3 to CAMK2-PLN-SERCA2a Ca2+ dyshomeostasis, extending cMLCK biology to drug-induced arrhythmia.\",\n      \"evidence\": \"iPSC-CMs with SQSTM1-MYLK3 co-immunoprecipitation, autophagy flux and phosphorylation assays, and rescue by MYLK3 overexpression or omecamtiv mecarbil\",\n      \"pmids\": [\"40568844\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal validation of the SQSTM1-MYLK3 interaction\", \"Direct mechanism coupling cMLCK to CAMK2 phosphorylation not defined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a GATA4-MYLK3-MYL2 transcriptional axis underlying osimertinib cardiotoxicity, broadening regulation of cMLCK to transcriptional repression.\",\n      \"evidence\": \"iPSC-CMs, TAC mouse model, single-nucleus RNA sequencing, and omecamtiv rescue\",\n      \"pmids\": [\"41330421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GATA4-MYLK3 link not confirmed by direct promoter binding assay\", \"Generalizability beyond osimertinib not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How cMLCK abundance is integrated across competing proteasomal, autophagic, microRNA, and transcriptional inputs to set MLC2v phosphorylation in different physiological and stress contexts remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of cMLCK turnover control\", \"E3 ligase mediating proteasomal degradation unidentified\", \"Direct kinase-level link between cMLCK and CAMK2 signaling unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 3, 6]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MYL2\", \"SQSTM1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}